Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sally Hartmanis

Sally Hartmanis

Sally Hartmanis

DPhil Student

Sally is a Doctor of Philosophy (DPhil) in Population Health candidate within the Health Economics Research Centre (HERC), under the supervision of Dr James Buchanan and Professor Sarah Wordsworth. 

Through her DPhil, Sally is exploring the valuation of outcomes associated with genome sequencing in economic evaluations. In particular, Sally is seeking to understand whether the existing ‘off-the-shelf’ instruments for deriving quality-adjusted life years (QALYs) are suitable for measuring the outcomes of genome sequencing, including health, non-health and process outcomes. In doing so, Sally will improve our understanding of the type and magnitude of outcomes arising from genome sequencing, and the instruments best suited to their ascertainment. This will provide health economists with clear guidance regarding how best to measure the outcomes of genome sequencing, and support funding bodies in considering these outcomes in their decision making to enable more efficient allocation of health sector resources. 

Sally is grateful to have been awarded a full scholarship in support of her studies funded by the Clarendon Fund, Mary Somerville Scholarship and a Department of Population Health Studentship. 

Prior to commencing her DPhil, Sally obtained a Bachelor of Biomedicine (genetics) from the University of Melbourne and a Master of Public Health (health economics) from Monash University, and gained eight years of work experience spanning health economics and social policy consulting (Deloitte), strategy consulting (IBM), medical research (Murdoch Children’s Research Institute, MCRI) and clinical research (GlaxoSmithKline, GSK).